UPCC 09220: Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Esophagogastric Adenocarcinoma
The purpose of this study is to test the effects of the research study drug Telomelysin (OBP-301) in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. Eligible subjects are those with advanced or metastatic cancer of the stomach or junction between the stomach and esophagus.
- Study Identifier: 843696
Recruitment StatusEnrolling By Invitation
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com